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Gam1The E1 helicase from BPV and HPV16 interacts with Ubc9 to facilitate viral genome replication. We report
that HPV11 E1 also interacts with Ubc9 in vitro and in the yeast two-hybrid system. Residues in E1 involved
in oligomerization (353–435) were sufﬁcient for binding to Ubc9 in vitro, but the origin-binding and ATPase
domains were additionally required in yeast. Nuclear accumulation of BPV E1 was shown previously to
depend on its interaction with Ubc9 and sumoylation on lysine 514. In contrast, HPV11 and HPV16 E1
mutants defective for Ubc9 binding remained nuclear even when the SUMO pathway was inhibited.
Furthermore, we found that K514 in BPV E1 and the analogous K559 in HPV11 E1 are not essential for
nuclear accumulation of E1. These results suggest that the interaction of E1 with Ubc9 is not essential for its
nuclear accumulation but, rather, depends on its oligomerization and binding to DNA and ATP.
© 2009 Elsevier Inc. All rights reserved.Introduction
Human papillomaviruses (HPV) are small double-stranded DNA
tumor viruses that cause benign and malignant lesions of the skin and
mucosa, notably cervical cancer (reviewed in Chow and Broker, 1997;
zur Hausen and de Villiers, 1994). Maintenance of the viral genome as
a circular episome in the nucleus of infected basal epithelial cells is
essential for the viral life cycle and the ensuing pathology (reviewed
in Howley, 1996; Shah and Howley, 1996; Stubenrauch and Laimins,
1999). Replication of the HPV genome is performed by two viral
proteins, E1 and E2, together with cellular DNA replication factors
(reviewed in Chow and Broker, 1994; Hebner and Laimins, 2006). E1
is the replicative helicase of the virus that, with the help of E2,
assembles into double hexamers at the origin of replication and
unwinds the DNA ahead of the bidirectional replication fork
(reviewed in Sverdrup and Myers, 1997; Wilson et al., 2002).
Structure–function studies indicated that E1 comprised at least
three functional domains. For HPV11 E1, these consist of an N-
terminal region (amino acids 1–191) essential for replication in vivoArchambault).
ll rights reserved.but dispensable in vitro, an origin DNA-binding domain (OBD, amino
acids 191–353), and a C-terminal helicase domain (amino acids 353–
649) sufﬁcient to form hexamers and to bind E2 (Amin et al., 2000;
Sun et al., 1998; Titolo et al., 2000, 1999, 2003b; White et al., 2003).
The helicase domain can be further subdivided into two regions. One
comprised of residues 353–435 of HPV11 E1 mediates the oligomer-
ization of the protein and constitutes the minimal E1–E1 interaction
domain that can be identiﬁed in the yeast two-hybrid system (Titolo
et al., 2000). The other, spanning amino acids 435–649, contains the
ATPase motifs conserved among members of the SF3 family of
helicases (Hickman and Dyda, 2005; James et al., 2003; White et al.,
2001). E1 also interacts with several cellular replication factors to
promote viral DNA replication, including polymerase α-primase, RPA,
and topoisomerase I (Amin et al., 2000; Clower et al., 2006; Conger
et al., 1999; Loo andMelendy, 2004; Masterson et al., 1998; Park et al.,
1994).
E1 was also reported to interact with Ubc9 suggesting that it may
be regulated by the Small Ubiquitin-like Modiﬁer (SUMO) pathway
(Rangasamy and Wilson, 2000; Yasugi and Howley, 1996; Yasugi
et al., 1997). Sumoylation is a process biochemically akin to
ubiquitination but involving the covalent attachment of SUMO to
speciﬁc lysines of target proteins (reviewed in Hochstrasser, 2002;
Kim et al., 2002; Schwartz and Hochstrasser, 2003). It has been shown
Fig. 1. Interaction of HPV11 E1 with Ubc9 in vitro. A schematic representation of the
HPV11 E1 protein, 649 amino acids in length, is shown at the top of the ﬁgure. The N-
terminal domain essential for in vivo replication (in vivo, amino acids 1–191), the origin
DNA-binding domain (OBD, amino acids 191–353) and the helicase domain encom-
passing a region required for oligomerization (O, amino acids 353–435) and ATPase
activity (amino acids 435–649) are indicated. Truncated E1 proteins that were tested
for interaction with Ubc9 in GST-pulldown assays are diagrammed as black boxes. The
region of HPV11 E1 essential for its interaction with Ubc9 in vitro is highlighted by a
grey box. The results of GST-pulldown assays performed with these truncations and the
percentage of input E1 bound to GST-Ubc9 (% E1 bound) are shown on the right of the
panel. In these experiments, in vitro translated and 35S-labeled E1 proteins were
chromatographed over GST or GST-Ubc9 columns and the bound proteins eluted with
high-salt were analyzed by SDS-PAGE and autoradiography. Fireﬂy luciferase (Luc) was
used as a negative control.
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chromosome segregation, cell cycle regulation, DNA replication, and
regulation of the activity of several transcription factors (reviewed in
Mascle et al., 2007;Matunis, 2002;Melchior and Hengst, 2002; Pichler
and Melchior, 2002; Seeler and Dejean, 2003; Verger et al., 2003;
Wilson and Rangasamy, 2001). The enzymology of sumoylation is
similar to that of ubiquitination but is accomplished by a different set
of activating (E1) and conjugating enzymes (E2) as well as E3 ligases
(reviewed in Geiss-Friedlander and Melchior, 2007; Hilgarth et al.,
2004). The human E1 activating enzyme is a heterodimer of the two
proteins SAE1 and SAE2. Interestingly, the Gam1 protein of the avian
adenovirus CELO (chicken embryo lethal orphan) has been shown to
interfere with cellular sumoylation by abrogating the function of this
heterodimer and inducing its ubiquitination and subsequent degra-
dation by the proteasome (reviewed in Chiocca, 2007). Ubc9 is the
only known SUMO-conjugating enzyme (E2) in yeast and human
(Desterro et al., 1997; Johnson and Blobel, 1997; Schwarz et al., 1998).
E3 ligases are dispensable in vitro where most of the substrate
speciﬁcity comes from the consensus sumoylation site itself, as
exempliﬁed by the crystal structure of Ubc9 in complex with a portion
of the target protein RanGAP1 (Bernier-Villamor et al., 2002; Sampson
et al., 2001). The consensus sequence for sumoylation is ψ-K-x-D/E in
which the lysine (K) subject to modiﬁcation is preceded by a
hydrophobic residue (ψ) and separated by any single amino acid (x)
from an aspartic or glutamic acid (D or E).
The interaction of papillomavirus E1 with human Ubc9 was
discovered in yeast two-hybrid screens, ﬁrst for the HPV16 protein
(Yasugi and Howley, 1996; Yasugi et al., 1997) and subsequently for
that of BPV (Rangasamy and Wilson, 2000). Sumoylation of E1 from
BPV, HPV1, and HPV18 has been demonstrated in vitro, in assays
performed with Ubc9, SUMO-1 and in vitro translated E1 (Rangasamy
and Wilson, 2000; Rangasamy et al., 2000). Sumoylation of BPV E1
was also shown to occur in vivo, in transfected cells overexpressing
E1, Ubc9 and SUMO-1 (Rangasamy and Wilson, 2000). The site of
SUMO attachment in BPV E1 was identiﬁed by mutagenesis as lysine
514, located in a highly conserved region of the C-terminal helicase
domain (Rangasamy et al., 2000). Substitution of lysine 514 for
alanine or arginine was shown to abrogate the ability of the protein to
support transient DNA replication in vivo (Rangasamy et al., 2000). A
similar result was obtained with a double amino acid substitution,
L420P/K421A, that weakens binding to Ubc9 in vitro and in yeast and
abrogates sumoylation in vitro and in vivo (Rangasamy and Wilson,
2000; Rangasamy et al., 2000). Strikingly, both the L420P/K421A and
K514R BPV E1 mutant proteins were found to accumulate in the
cytoplasm rather than in the nucleus of transfected COS-1 cells, when
fused to GFP (Rangasamy et al., 2000). These studies led to the
proposal that interactionwith Ubc9 and conjugationwith SUMO-1 are
required for intranuclear accumulation of BPV E1.
Here we report that that HPV11 E1 also interacts with Ubc9 and
provide evidence that the ability of E1 to oligomerize and to bind DNA
and ATP is required for this interaction. We also demonstrate that the
nuclear accumulation of E1 is not dependent on its interaction with
Ubc9 and on a functional SUMO pathway in C33A cervical carcinoma
cells.
Results and discussion
HPV11 E1 binds to human Ubc9 in vitro through a region required for its
oligomerization
To determine if HPV11 E1 could interact with Ubc9 similarly to
what was observed for BPV and HPV16 E1, we ﬁrst performed an in
vitro binding assay using GST-Ubc9 puriﬁed from bacteria and in vitro
translated E1 produced in a rabbit reticulocyte lysate. Using this
pulldown assay, a positive interaction was detected between both
proteins (Fig. 1). The speciﬁcity of this interaction was demonstratedby showing that E1 did not bind to GST alone and that GST-Ubc9 could
not pulldown an unrelated protein, ﬁreﬂy luciferase (Luc). We also
showed that the E1-Ubc9 interaction was not sensitive to ethidium
bromide in vitro (data not shown), indicating that it is not
artefactually mediated through DNA present in the E1 lysate. We
then used the set of deletions shown in Fig. 1 to map the domain of
HPV11 E1 required for binding to Ubc9. E1 fragments were tested for
their binding to puriﬁed GST-Ubc9, or to GST alone as a control.
Among the N-terminally truncated E1 fragments, the one comprised
of amino acids 353–649 was the shortest one that retained binding to
Ubc9 (Fig. 1). For the C-terminally truncated fragments, we found that
the one comprised of the ﬁrst 458 amino acids of E1 could bind to
Ubc9, whereas a shorter one ending at amino acid 344 could not
(Fig. 1). Incidentally, the fact that an E1 fragment lacking the ATPase
domain (amino acids 435–649), which is essential for single-stranded
DNA binding (Enemark and Joshua-Tor, 2006), could still interact with
Ubc9 ruled out the possibility that the interaction was artefactually
mediated by single-strandedDNApresent in the E1 lysate. Collectively,
these studies indicate that amino acids 353–435 of HPV11 E1 are
required for interaction with Ubc9. Interestingly, we previously
reported that this region is also required for the oligomerization of
E1 into hexamers (Titolo et al., 2000).
HPV11 E1 interacts with human Ubc9 in the yeast two-hybrid system
We determined that HPV11 E1 also interacts with Ubc9 in the
yeast two-hybrid system, giving rise to high levels of β-galactosidase
Fig. 2. Interaction of HPV11 E1 with Ubc9 in the yeast two-hybrid system. A schematic representation of the HPV11 E1 protein is shown at the top of the ﬁgure, as described in the
legend of Fig. 1. Truncated E1 proteins tested for interaction with Ubc9 in the yeast two-hybrid system are diagrammed as black boxes. The level of expression of the different E1
fragments (Supplementary Fig. 1) are summarized on the left as low (+), intermediate (++), and high (+++) expression level. Yeast two-hybrid results are indicated on the right
of each truncation as relative levels of β-galactosidase activity measured in cells expressing either human Ubc9 fused to the Gal4 activation domain (AD-Ubc9) or the Gal4 activation
domain (AD) alone. The value for the interaction between E1 and a mutant Ubc9, carrying the C93S (Mut) substitution in the site of thioester linkage, is indicated in parentheses. All
values are presented relative to that obtained for the combination of E1 (72–649) and Ubc9, which was set arbitrarily at 100. Negative and positive controls were the Gal4-DBD and
BPV E1 (amino acids 1–605), respectively.
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previously reported, the complete HPV11 E1 protein (1–649) can
activate transcription by itself in yeast, although not to an extent that
prevents detection of its interaction with Ubc9 (Titolo et al., 1999).
Fortunately, the interaction was conserved with a shorter HPV11 E1
fragment that lacks the ﬁrst 71 amino acids and does not activate
transcription in yeast. We also found that the interaction is
independent of Ubc9 enzymatic activity since this E1 fragment
could also interact with an inactive form of Ubc9 carrying the amino
acid substitution C93S at the site of thioester linkage (Chakrabarti et
al., 1999) (Fig. 2). The domain of HPV11 E1 required for interaction
with Ubc9 was then mapped using a series of deletions shown in
Fig. 2. These studies revealed that a fragment spanning amino acids
191–649 was the smallest region of E1 that gave rise to high levels of
β-galactosidase activity in presence of Ubc9. This fragment of E1
encompasses the origin-binding domain (OBD; amino acids 191–353)
and the C-terminal helicase domain (amino acids 353–649). Inter-
estingly, the E1 (191–649) fragment and all of the larger ones that
interacted strongly with Ubc9 were only weakly expressed in yeast
(Supplementary Fig. 1). Truncations that removed part of the ATPase
region (72–572) or the OBD (353–649) resulted in substantially lower
levels of β-galactosidase activity, suggesting that both domains are
necessary for interaction with Ubc9. Neither the OBD nor the C-
terminal helicase domain interacted strongly with Ubc9 although low
levels of β-galactosidase activity were measured for both domains,
suggesting that they can each interact weakly with Ubc9. A fragment
encompassing the OBD and minimal E1–E1 oligomerization domain
(191–438) gave rise to higher levels of β-galactosidase activity in
presence of Ubc9 than the OBD alone (191–353), despite the fact that
it was expressed at lower levels than the OBD (Supplementary Fig. 1).
This ﬁnding re-enforces the role of amino acids 353–438 for
interaction with Ubc9. Collectively, these results indicate that an E1fragment encompassing the OBD, minimal E1 oligomerization
domain, and ATPase motifs interacts robustly with Ubc9 and that all
three regions participate in this interaction.
Effect of single amino acid substitutions in HPV11 E1 on its interaction
with Ubc9 in vitro and in yeast
The results presented above identiﬁed amino acids 353–435 of E1
as important for Ubc9 binding in vitro and in yeast (Fig. 3A).
Furthermore, they revealed that the OBD and ATPase region also
contribute to the E1–Ubc9 interaction in yeast (Fig. 3A). To
substantiate these ﬁndings, we tested the effect of single amino acid
substitutions in E1 that impair its origin binding, oligomerization or
ATPase activity on its interaction with Ubc9 in vitro and in yeast (Figs.
3B and C). For BPV E1, it was previously shown that the K183A
substitution in the OBD abrogates origin binding (Gonzalez et al.,
2000). We therefore created the analogous amino acid substitution
(K228A) in HPV11 E1, conﬁrmed that it abrogates origin binding (see
below), and analyzed its effect on the E1–Ubc9 interaction. We found
that this substitution reduced the binding of HPV11 E1 to Ubc9 both in
pulldown assays (Fig. 3B) and in yeast (Fig. 3C), thereby conﬁrming a
role for the OBD in this interaction. To investigate the role of E1
oligomerization in its interaction with Ubc9, we used previously
described amino acid substitutions, Y380A, N389A, and F393A that
abolish the oligomerization of HPV11 E1 (Titolo et al., 2000; White
et al., 2001). These three substitutions also affect the ATPase activity of
HPV11 E1 (Titolo et al., 2000; White et al., 2001) as E1 needs to
assemble into hexamers to be enzymatically active. We found that the
three substitutions reduced interaction of E1 to Ubc9 in vitro and
yeast, conﬁrming a role for the oligomerization domain in Ubc9
binding. We previously demonstrated that these substitutions do not
affect the interaction of E1 with E2 (Titolo et al., 2000), indicating that
Fig. 3. Amino acid substitutions affecting the interaction of HPV11 E1 with Ubc9. (A)
Diagram of HPV11 E1 highlighting the portion of the protein required for interaction
with Ubc9 in vitro (amino acids 353–435) and in the yeast two-hybrid system (amino
acids 191–649). (B) GST-pulldown assays showing the binding of wild-type (WT) and
the indicated mutant E1 proteins to GST-Ubc9 or GST as a control. The percentage of
input E1 bound to GST-Ubc9 (% E1 bound) is shown on the right of the panel. (C) Yeast
two-hybrid results showing the interaction of wild-type and mutant E1 (72–649)
proteins with Gal4 AD-Ubc9 or the Gal4 AD alone as a control. β-Galactosidase levels
are reported as a percentage of those measured in cell expressing wild-type E1 (72–
649) and AD-Ubc9.
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tested the effect of mutating the highly conserved K484 residue of the
HPV11 E1 Walker A ATPase motif that is predicted to make critical
hydrogen bounds with the triphosphate tails of ATP (Enemark and
Joshua-Tor, 2006; James et al., 2003, 2004). Substitution of K484 for
either alanine or arginine had no effect on the interaction of E1 with
Ubc9 in vitro but completely abolished it in yeast. This result provided
further support that the ATP-binding activity of E1 is needed for its
interaction with Ubc9 in yeast. Together, the results described above
support the notion that the minimal E1 oligomerization domain
contains a binding site for Ubc9 that is sufﬁcient for interaction in
vitro. This domain of E1 is also required for interaction with Ubc9 in
yeast but additional sequences in the origin-binding domain and C-
terminal ATPase domain of E1 are also needed formaximal interaction
(i.e., for high levels of β-galactosidase activity).
Nuclear accumulation of HPV11 E1 is not affected by substitutions that
weaken Ubc9 binding and by inhibition of the SUMO pathway
It was previously reported that intranuclear accumulation of BPV
E1 is dependent on its interaction with Ubc9 (Rangasamy andWilson,
2000; Rangasamy et al., 2000). We therefore examined the intracel-
lular localization of the HPV11 E1mutant proteins described above. As
was done in the BPV study, we chose to visualize HPV11 E1 by fusing it
to GFP.Wewere cautious to use a GFP-E1 construct in which a splicing
donor site within the E1 ORF had been inactivated by silent mutations
to prevent expression of a truncated fusion protein (Cote-Martin et al.,
2008; Deng et al., 2003) and veriﬁed proper expression of each GFP-E1 protein by Western blotting (Supplementary Fig. 2A). In
transfected C33A cells, this GFP-HPV11 E1 fusion protein was nuclear
(Fig. 4), as previously reported (Deng et al., 2003). We also observed
that the HPV11 E1 mutant proteins defective for Ubc9 binding were
nuclear (Fig. 4), in contrast to what would have been expected from
the BPV study (Rangasamy andWilson, 2000; Rangasamy et al., 2000).
These results suggested that nuclear accumulation of HPV11 E1 is
independent of its interaction with Ubc9.
Given that the primary function of Ubc9 is to conjugate SUMO to
its target proteins (Johnson, 2004) and that the nuclear accumulation
of HPV11 E1 is independent of its interaction with Ubc9, we surmised
that nuclear accumulation of E1 was independent of the SUMO
pathway. To conclusively rule out the involvement of the SUMO
pathway in HPV11 E1 nuclear accumulation, we initially used the
Gam1 protein of the CELO adenovirus, a known inhibitor of the
SUMO-activating enzyme (SAE1/SAE2 heterodimer) (reviewed in
Chiocca, 2007). First, we conﬁrmed that expression of Gam1 could
inhibit the SUMO pathway in C33A cells by showing that it could
prevent the sumoylation of the promyelocytic leukemia protein
(PML), a prototypical substrate of the SUMO pathway, and also
disrupt its characteristic punctuate intranuclear localization. Specif-
ically, we showed by Western blotting that Gam1 could effectively
inhibit the accumulation of the sumoylated forms of PML in C33A
cells, 24 h post-transfection (Fig. 5A). PML is known to accumulate in
discrete nuclear foci known as nuclear domains 10 (ND10) or PML
oncogenic domains (PODs) (Zhong et al., 2000) whose formation
depends on the sumoylation of PML (Shen et al., 2006). To further
demonstrate that Gam1 was capable of inhibiting the SUMO pathway
in C33A cells, we showed that its cotransfection resulted in the
redistribution of GFP-PML from discrete nuclear foci to the nuclear
periphery and in larger intranuclear domains (Figs. 4 and 5B), similar
to what was reported by Shen et al. (2006). Together, these results
demonstrated that Gam1 was indeed inhibiting the SUMO pathway
under our assay conditions. When cotransfected with GFP-E1, Gam1
had no effect on the nuclear accumulation of wild-type E1 in C33A
cells (Figs. 4 and 5B), suggesting that the SUMO pathway is not
involved in this process. To exclude the possibility that residual
activity of the SUMO pathway was responsible for the nuclear
accumulation of HPV11 E1, we also veriﬁed that the effect of Gam1
on PML and HPV11 E1 was the same at 48 h post-transfection. At this
time point, sumoylation of PML was still inhibited and its cellular
localization was disturbed (Fig. 5). However, the nuclear accumula-
tion of HPV11 E1 remained unchanged, further supporting the notion
that HPV11 E1 nuclear accumulation is independent of the SUMO
pathway.
To rule out any potential pleiotropic effect of Gam1, we used two
additional methods of interfering with the SUMO pathway. First, we
made use of a dominant negative version of Ubc9 (Ubc9dn, C93S) that
can still interact with its target proteins, including E1 (Fig. 2), but is
unable to conjugate SUMO (Chakrabarti et al., 1999). As expected,
Ubc9dn, but not Ubc9WT, signiﬁcantly reduced the sumoylation of
PML and led to a redistribution of GFP-PML at the nuclear periphery
and in larger intranuclear domains 24 and 48 h post-transfection
(Supplementary Fig. 3B). Importantly, it had no effect on the
intranuclear accumulation of E1 (Supplementary Fig. 3B). We then
tested the effect of depleting the levels of Ubc9 in C33A cells using a
speciﬁc shRNA (shUbc9 11077, Supplementary Fig. 4A). As anticipat-
ed, the Ubc9 shRNA, but not the inactive control shRNA, led to a
redistribution of PML 96 h post-transfection but had no effect on the
intranuclear accumulation of E1 (Supplementary Fig. 4B). From these
studies, we conclude that a functional SUMO pathway is not required
for nuclear accumulation of wild-type HPV11 E1.
Next, we wondered if HPV11 E1 mutants that are defective for
Ubc9 binding would be more sensitive to inhibition of the SUMO
pathway.We therefore investigated the nuclear accumulation of these
E1 mutants in the presence of Gam1, which we have found is a
Fig. 4. Intracellular localization of wild-type andmutant HPV11 E1. C33A cells transiently expressing the indicated GFP-HPV11 E1 proteins, or GFP-PML, with or without Gam1, were
ﬁxed, mounted, and visualized by ﬂuorescence confocal microscopy. Nuclei (DNA) were stained with TO-PRO-3.
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shRNA. We found that all of the Ubc9-binding defective E1 mutants
were still localized to the nucleus when the SUMO pathway was
inhibited by Gam1 (Fig. 4). Collectively, these results indicate that the
nuclear accumulation of HPV11 E1 is independent of both its
interaction with Ubc9 and a functional SUMO pathway.
Mutant HPV16 E1 proteins that are defective for interaction with Ubc9
also localize to the nucleus
One of our laboratories has previously identiﬁed ﬁve amino acid
substitutions in HPV16 E1 that abrogate its interaction with Ubc9 in
the yeast two-hybrid system (Yasugi et al., 1997). Of these substitu-tions, four lie in the C-terminal helicase domain (Y412F, W439R,
G482D, and G496R) whereas the ﬁfth one is in the OBD (S330R). To
analyze the nuclear accumulation of these mutant HPV16 E1, we
constructed GFP fusion proteins in which themajor splicing donor site
within the E1 ORF was mutated to prevent expression of a truncated
fusion protein, essentially as we did for HPV11 E1 (Cote-Martin et al.,
2008), and veriﬁed their proper expression by Western blotting
(Supplementary Fig. 2B). We then determined their intracellular
localization in C33A cells. We found that the wild-type GFP-HPV16 E1
fusion protein localizes predominantly to the nucleus and that this
phenotype was not altered by amino acid substitutions that affect
Ubc9 binding (Fig. 6). Furthermore, expression of Gam1 did not affect
the nuclear accumulation of either wild-type or mutant E1 (Fig. 6).
Fig. 5. Effect of the Gam1 protein on PML sumoylation and intracellular localization of PML and HPV11 E1. (A) Sumoylation of PML. C33A cells were transfected with a plasmid
encoding a triple Flag-tagged PML (3F-PML) either alone or together with a plasmid encoding Myc-Gam1. Anti-Flag, anti-tubulin, and anti-Myc immunoblots were performed on
whole cell extracts (WCE) 24 and 48 h post-transfection. (B) Cellular localization of PML and HPV11 E1. C33A cells transiently expressing GFP–E1 or GFP-PML, with or without Gam1,
were ﬁxed, mounted, and visualized by ﬂuorescence confocal microscopy 24 and 48 h post-transfection. Nuclei (DNA) were stained with TO-PRO-3.
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nuclear accumulation of GFP-HPV16 E1, even in presence of Gam1,
provides strong evidence that this process can occur independently of
an interaction with Ubc9 and a functional SUMO pathway, similarly to
what we observed for HPV11 E1.
The S330R substitution in the HPV16 E1 OBD reduces its afﬁnity for DNA
In this study, we found that mutations that affect the oligomer-
ization of HPV11 E1 also impair Ubc9 binding. A similar observation
was made by Yasugi et al. (1997), who found that four of their ﬁve
substitutions in HPV16 E1 that affected interaction with Ubc9 also
affected oligomerization of the protein, detected as an E1–E1
interaction in the yeast two-hybrid system. Accordingly, these four
mutant proteins showed reduced ATPase activity and were unable to
support transient DNA replication (Yasugi et al., 1997). In contrast the
ﬁfth substitution, S330R, impaired the interaction of E1 with Ubc9
with little effect on its ATPase activity and oligomerization (Yasugi et
al., 1997). The S330R substitution was also unique in that it conferred
a dominant negative phenotype in transient DNA replication assays,
unlike the other mutants (Yasugi et al., 1997). Since S330R lies in the
OBD, albeit in a region opposite to the DNA-binding surface (Fig. 7A),we wondered if it had any effect on its afﬁnity for DNA. To test this
possibility, we produced and puriﬁed the wild-type and S330R HPV16
E1 OBDs (residues 190–352) fused to GST. For comparison, we also
produced the analogous wild-type and mutant (S331R) OBD from
HPV11. An HPV11 OBD carrying the K228A substitution, which lies
near the DNA-binding surface (Fig. 7A), was also produced as a DNA-
binding defective control. The DNA-binding activities of these
different OBDs were then measured using a quantitative assay
based on ﬂuorescence anisotropy, which we previously described
(Titolo et al., 2003a). In this assay, binding of the puriﬁed GST-E1 OBD
to a 21-bp duplex DNA labeled at one end with ﬂuorescein results in a
change in anisotropy that reaches a plateau when all of the binding
sites are occupied. The ﬂuorescent duplex DNA used in these
experiments contained two inverted E1 binding sites separated by
3 bp, (5′-Fluo-GGATACTTAATAATAATGGGC-3; the two binding sites
are underlined), an optimal substrate for the GST-OBD (Titolo et al.,
2003a). As expected, we observed that the wild-type HPV16 E1 OBD
could readily bind to the probe, with an estimated dissociation
constant (KD) of 875±100 nM (Fig. 7B). In contrast, the S330Rmutant
OBD had a much lower afﬁnity for the probe, too weak to be
accurately measured (Fig. 7B). These results indicate that the S330R
substitution reduces the afﬁnity of the E1 OBD for DNA. Similar results
Fig. 6. Intracellular localization of wild-type and mutant HPV16 E1. C33A cells transiently expressing the indicated GFP–HPV16 E1 proteins, or GFP-PML, with or without Gam1 were
ﬁxed, mounted, and visualized by ﬂuorescence confocal microscopy. Nuclei (DNA) were stained with TO-PRO-3.
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mutant was also inactive similar to the control mutant K228A. Since
S330R affects the binding of HPV16 E1 to Ubc9 in the yeast two-hybrid
system, these results provide additional evidence that the DNA-
binding activity of E1 is required for interaction with Ubc9 in yeast. In
addition, the fact that the S330R substitution reduces DNA binding
(this study), while having little effect on the oligomerization of E1 or
its interaction with E2 (Yasugi et al., 1997), provides a likely
mechanism for its dominant negative phenotype in transient DNA
replication assays (Yasugi et al., 1997).
Nuclear accumulation of BPV E1 is independent of the SUMO pathway
and of lysine 514 in C33A cells
Our ﬁnding that nuclear accumulation of HPV11 and HPV16 E1 is
independent of Ubc9 binding and of the SUMO pathway is in contrast
to what has been reported for BPV E1 by Rangasamy and Wilson
(2000) and Rangasamy et al. (2000). This prompted us to re-examine
the intracellular localization of BPV E1 in C33A cells, under our assay
conditions. As expected, we observed that BPV E1, when fused to GFP
as was done by Rangasamy and Wilson (2000) and Rangasamy et al.
(2000), accumulated in the nucleus of transfected C33A cells.
Surprisingly, however, BPV E1 remained nuclear when the SUMO
pathway was inhibited by Gam1. It was previously reported that BPV
E1 is sumoylated on lysine 514 and that substitution of this residue foreither alanine or arginine abrogates its nuclear accumulation
(Rangasamy et al., 2000). When tested for their effect in C33A cells,
we observed that neither of the two K514 substitutions had an effect on
the nuclear accumulation of BPV E1, even when the SUMO pathway
was inhibited by Gam1 (Fig. 8). We also investigated if similar
substitutions had any effect in the context of HPV11 E1. As was
observed for BPV E1 both HPV11 mutants (K559A and K559R)
accumulated in the nucleus of transfected cells even in presence of
Gam1 (Fig. 8). From these results, we conclude that nuclear
accumulation of BPV and HPV11 E1 is not dependent on a functional
SUMO pathway and on the integrity of K514/K559 in C33A cells,
regardless of whether K514/K559 is a site of sumoylation in these cells.
The ﬁnding presented above promoted us to test more directly if
BPV and HPV11 E1were sumoylated in C33A cells. We found that both
proteins, either in their wild-type or mutant forms (K514/K559),
were not signiﬁcantly sumoylated in C33A cells as compared to PML,
which was used as a positive control in these experiments
(Supplementary Fig. 5). We cannot rule out that a very small amount
of E1 sumoylation occurs in C33A cells, below the detection limit of
our assay. However, if this were the case, we would anticipate that
this low level of sumoylation would be very efﬁciently inhibited by
Gam1 as this adenoviral protein can inhibit the much more robust
sumoylation of PML (Fig. 5A). Overall, these ﬁndings provide further
support to the idea that nuclear accumulation of E1 is independent of
sumoylation in C33A cells.
Fig. 7. Effect of the S330R and S331R substitutions on the DNA-binding activity of the
HPV16 and HPV11 E1 OBD, respectively. (A) Location of S330/S331 and K228 in the
structure of the OBD. Crystal structure of the BPV E1 OBD bound to DNA (PDB ID: 1KSY
(Enemark et al., 2002)) showing the location of threonine 286 (in yellow), which is
analogous to serine 330 and 331 in HPV16 and HPV11 E1, respectively. The location of
lysine 183, analogous to lysine 228 in HPV11 E1, is shown in red. (B) Fluorescence
anisotropy DNA-binding assays. Binding isotherms were performed with 10 nM of
ﬂuorescent DNA probe containing two E1 binding sites and increasing concentrations of
puriﬁed wild-type (squares) or S330R (triangles) GST-HPV16 OBD. (C) Same as panel B
but using the wild-type GST-HPV11 E1 OBD (squares) or mutant derivatives carrying
the K228A (circles) or S331R (triangles) amino acid substitution. Each binding isotherm
was performed in triplicate.
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replication
K514 in BPV E1 has been shown to be essential for viral DNA
replication. Speciﬁcally, it was reported that BPV E1 mutants carrying
the K514A and K514R substitutions were unable to support transientBPV DNA replication (Rangasamy et al., 2000). Because K514 is highly
conserved (Fig. 9A), we tested if this residue was also essential for
viral DNA replication in the context of HPV11 E1. Surprisingly, we
found that the K559A and K559R substitutions had little effect in a
transient HPV DNA replication assay performedwith untagged HPV11
E1 and E2 (Figs. 9B and C). The fact that the K559A and K559R mutant
E1 were nearly as active as their wild-type counterpart indicated that
not only are they functional but also that they must localize to the
nucleus where viral DNA replication takes place. Consistent with the
fact that the two K559 mutant E1 are functional, they both retained
the ability to interact with Ubc9 in vitro and in yeast (Figs. 9D and E).
Thus, unlike what was found for BPV E1, K559 is not essential for
HPV11 E1's ability to support viral DNA replication.
Concluding remarks
In this report, we provide evidence that HPV11 E1 interacts with
the human SUMO-conjugating enzyme Ubc9 in yeast and in vitro,
similarly to what was reported for HPV16 and BPV E1 (Rangasamy
and Wilson, 2000; Yasugi and Howley, 1996; Yasugi et al., 1997). We
determined that the region of HPV11 E1 spanning amino acids 353–
435 is important for interaction with Ubc9 both in yeast and in vitro,
in agreement with the mapping data reported for BPV E1, which
implicated residues 315 to 459 (corresponding to amino acids 360 to
504 of HPV11 E1). In addition to this region, we found that the OBD
and the ATPase domain of E1 are also required for the interaction of E1
with Ubc9 in yeast, although both domains are dispensable in vitro.
Based on our previous experience in using the yeast two-hybrid
system and in vitro GST-pulldown assays to characterize protein–
protein interactions, we would argue that the E1–Ubc9 interaction
gives rise to a robust β-galactosidase signal in yeast but to weaker
binding in pulldown assays. One reason for this difference may be the
oligomerization status of E1. We previously determined that in vitro
translated E1 is mostly monomeric (Titolo et al., 2000), and this may
explain why it interacts only weakly with Ubc9 in pulldown assays. In
yeast, interaction with Ubc9 may be enhanced by oligomerization of
E1, which we have shown previously to occur in the two-hybrid
system (Titolo et al., 2000). Interestingly, we also reported before that
amino acids 353–435 of HPV11 E1, which we determined here to be
necessary for interaction with Ubc9, mediate the oligomerization of
E1 (Titolo et al., 2000). Furthermore, we have found in this study that
substitutions in this region that abrogate the oligomerization of E1
(Y380A, N389A, and F393A) also prevent its interaction with Ubc9
(Titolo et al., 2000). Collectively, these ﬁndings suggest that the ability
of E1 to oligomerize and bind to Ubc9 may be functionally related. We
previously showed that the oligomerization of E1, as well as its ATPase
activity, is abolished by substitution of the ATPase Walker A residue
K484 to either alanine or arginine (Titolo et al., 2000; White et al.,
2001). Here we found that these same substitutions also affect the
interaction of E1 with Ubc9 in yeast. Similarly, four of the ﬁve
substitutions in HPV16 E1 that reduce its interaction with Ubc9 in
yeast also inhibit its oligomerization (E1–E1 interaction in yeast) and
ATPase activity (Yasugi et al., 1997). Collectively, these results support
the notion that oligomerization and ATP-binding/hydrolyzing activity
of E1 are needed for its robust interaction with Ubc9 in yeast. Based on
the two-hybrid and in vitro interaction data, we propose that residues
353–435 of E1 contain the primary binding site for Ubc9 and that this
interaction can be further modulated by oligomerization of the protein.
We also observed that the OBD can modulate the interaction of
E1 with Ubc9 in the yeast two-hybrid system. This is most obvious
when comparing an HPV11 E1 fragment containing both the OBD
and helicase domain (aa 191–649) to one encompassing the
helicase domain alone (aa 353–649). Although both E1 fragments
bind to GST-Ubc9 with comparable afﬁnities in vitro, the larger one
gives rise to substantially higher levels of β-galactosidase activity in
yeast, suggesting that it interacts more efﬁciently with Ubc9. The
Fig. 8. K559 and K514 are not essential for the intracellular localization of HPV11 and BPV E1, respectively, in C33A cells. C33A cells transiently expressing the indicated GFP–E1
proteins, or GFP-PML, with or without Gam1, were ﬁxed, mounted, and visualized by ﬂuorescence confocal microscopy. Nuclei (DNA) were stained with TO-PRO-3.
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HPV11 K228A and HPV16 S330R substitution that abrogate the DNA-
binding activity of the OBD also weakens the E1–Ubc9 interaction in
yeast. Thus the origin-binding activity of both HPV11 and HPV16 E1
is essential for their interaction with Ubc9 in yeast. Given that we
previously demonstrated that the OBD modulates the oligomeriza-
tion of E1 (Titolo et al., 2000), it may not be surprising that it also
affects its interaction with Ubc9 in yeast.
Previous studies on BPV E1 suggested that nuclear accumulation of
the protein was dependent on its interaction with Ubc9 and
sumoylation on lysine 514 (Rangasamy et al., 2000). In contrast to
what was reported for BPV E1, we found that lysine 559 of HPV11 is
neither required for the replication activity of the protein nor for its
nuclear accumulation. More importantly, we found that HPV11 and
HPV16 E1 proteins defective for Ubc9 binding could still accumulate
in the nucleus, even when the SUMO pathway was inhibited by the
Gam1 protein of the CELO adenovirus. The lack of effect of Gam1 is
consistent with our observation that HPV11 E1 proteins are not
signiﬁcantly sumoylated in C33A cells even when the SUMO
conjugation capacity of these cells is augmented by co-expression of
Ubc9 and SUMO-1. Collectively, our ﬁndings indicate that nuclear
accumulation of HPV11 and HPV16 E1 can occur independently of
their sumoylation and interaction with Ubc9. Surprisingly, we also
observed that the nuclear accumulation of BPV E1 was not changed by
Gam1 or by mutation of lysine 514 in C33A cells, in contrast to what
was reported previously in COS-1 cells (Rangasamy et al., 2000). This
discrepancy between the two studies is unlikely due to our use of a
GFP-E1 fusion protein, since a similar fusion was used in the BPV
study. Furthermore, Deng et al., 2003 have shown that HPV11 E1
remains functional in transient DNA replication assays when fused to
GFP. Our localization studies were performed in C33A cervicalcarcinoma cells, rather than in the COS-1 monkey kidney cells,
because we believe that the C33A cell line is a more relevant system in
which to study the function and regulation of HPV proteins. In support
of our ﬁndings, we note that Yu et al. (2007) also observed that the
K559A and K559R substitutions in HPV11 E1 have no effect on nuclear
accumulation of the protein, in their case in COS-7 cells. We further
note that the group that described the nuclear accumulation defect of
the K514 BPV E1 protein has recently published that this mutant E1 is
nuclear (Rosas-Acosta and Wilson, 2008). Finally, we stress that the
nuclear accumulation of HPV11 and HPV16 E1 was unaffected by the
combined effect of mutations that prevent Ubc9 binding and
inhibition of the SUMO pathway by Gam1, thus providing strong
evidence that sumoylation of E1 is not required for its nuclear
accumulation.
In summary, the fact that all of the Ubc9-binding defective E1
mutants identiﬁed so far are unable to support viral DNA replication
(Titolo et al., 2000; Yasugi et al., 1997), despite being in the nucleus,
suggests that Ubc9 is required for some, yet unidentiﬁed, aspects of
viral DNA replication. In addition, the results in this manuscript
indicate that the interaction of E1 with Ubc9 depends on its
oligomerization and binding to DNA and ATP (Titolo et al., 2000;
Yasugi et al., 1997). Together, these ﬁndings support a model whereby
Ubc9 facilitates viral DNA replication at a step following assembly of
E1 into a double hexamer at the origin.
Materials and methods
Plasmid constructions and mutagenesis
Plasmids to express GFP–E1 fusion proteins were constructed by
inserting PCR fragments encoding the HPV11 and BPV1 E1 ORFs into
Fig. 9. K559 is not essential for the replication activity of HPV11 E1. (A) Sequence alignment showing the conservation of K559 in the E1 proteins from different papillomaviruses. (B)
Transient HPV11 DNA replication. Cells were transfected with expression plasmids for the indicated wild-type or mutant HPV11 E1 together with an E2-expression plasmid and an
origin-containing plasmid. The amount of replicated origin plasmid was measured by PCR from DpnI-digested genomic DNA. A portion of the E1-expressing plasmid devoid of DpnI
site was ampliﬁed as an internal control to normalize for variation in transfection efﬁciencies. Each E1 mutant was tested in quadruplicates. The ﬁgures show the amounts of origin
(ori) and E1 PCR products separated on 1% agarose gels and stained with the ﬂuorescent dye SYBRGreen I (Molecular Probes). The HPV11 E1 K228Amutant defective in DNA binding
was used as negative controls. (C) DNA replication activity of mutant E1 proteins. The intensities of the ori and E1 PCR fragments shown in panel B were quantiﬁed using a Storm
PhosphorImager (Amersham Biosciences) and used to calculate the replication activity of each mutant protein relative to that of wild-type E1, which was set at 100%. Each value is
the average of four replicates with the standard deviation indicated. (D) GST-pulldown assays showing the binding of wild-type (WT) and the indicated mutant E1 proteins to GST-
Ubc9 or GST as a control. The percentage of input E1 bound to GST-Ubc9 (% E1 bound) is shown on the right of the panel. (E) Yeast two-hybrid results showing the interaction of wild-
type andmutant E1 (72–649) proteins with Gal4 AD-Ubc9 or the Gal4 AD alone as a control. β-Galactosidase levels are reported as a percentage of those measured in cell expressing
wild-type E1 (72–649) and AD-Ubc9.
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E1 ORF in these constructs carries silent mutations at codons 5–6
(nucleotides 844–849) that inactivate an internal splicing donor site,
which, if not mutated, leads to expression of a truncated GFP–E1
protein (Deng et al., 2003). Plasmids to express GFP–HPV16 E1 fusion
proteins were construct by inserting PCR fragment encoding the
HPV16 E1 ORF into plasmid pGFP2-C2 (Perkin-Elmer) using XhoI and
BamHI. The HPV16 E1 ORF in these constructs also carries silent
mutations at codons 5–6 (nucleotides 877–882) to inactivate an
internal splicing donor site and prevent expression of a truncatedGFP–
E1 protein (data not shown). Plasmids to express the HPV16 E1 OBD
(amino acids 190–352) and HPV11 E1 OBD (amino acids 191–353)
fused to GST have been described (Titolo et al., 2003a). Site-directed
mutagenesis was performed with the QuickChange Site-Directed
Mutagenesis kit (Stratagene) according to the manufacturer's instruc-
tions. All DNA constructs were veriﬁed by sequencing. Plasmids
expressing 21-nucleotide short hairpin RNAs (shRNA) against Ubc9were expressed from the pLKO.1-Puro plasmid and obtained from
Open Biosystems (Cat: RHS4533-NM_003345). The targeting
sequences for the shRNA against Ubc9 are available online and the
targeting sequence for the shRNA control is 5′-GCTATGAGAATAACGG-
TAACA-3′. Details on construction of these plasmids will be made
available upon request.
Yeast two-hybrid analysis
Yeast two-hybrid analysis was performed using Saccharomyces
cerevisiae strain Y153 (MATa leu2-3,112 ura3-52 trp1-901 his3-Δ200
ade2-101 gal4Δ gal80Δ URA3::GAL-lacZ LYS::GAL-HIS3) as described
(Titolo et al., 1999). β-Galactosidase assays were performed with the
substrate chlorophenol red-β-D-galactopyranoside (Roche Applied
Science) as described (Titolo et al., 1999). HPV11 E1 plasmids have
been described (Titolo et al., 1999, 2000). Plasmids encoding BPV E1
and human Ubc9 fused to the Gal4 DNA-binding domain and
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(Texas A&M) and have been described (Rangasamy and Wilson,
2000).
GST-pulldown assay
GST and GST-Ubc9 proteins were puriﬁed from Escherichia coli
BL21 (DE3) (Novagen) as previously described (Titolo et al., 2000).
GST-pulldown assays were performed as described in Titolo et al.
(2000). The GST-Ubc9 plasmid was a kind gift from Dr. Van Wilson
(Texas A&M) and has been described (Rangasamy andWilson, 2000).
Plasmids used for in vitro translation of E1 have been described
(Titolo et al., 2000).
Cell culture and transfections
The human cervical carcinoma cell line C33A was grown in
Dulbecco's modiﬁed Eagle's medium supplemented with 10% fetal
bovine serum, 0.5 IU/ml of penicillin, 50 µg/ml streptomycin, and
2 mM L-glutamine. Transfections of C33A cells were performed using
the Lipofectamine 2000 reagent (Invitrogen).
Confocal ﬂuorescence microscopy
C33A cells (8×106) were transfected with 400 ng of GFP–E1
expression plasmid and either 400 ng of Gam1 expression plasmid or
the same amount of empty vector as control, and grown on coverslips.
Twenty-four hours post-transfection cells were ﬁxed with 4%
formaldehyde and permeabilized with 0.2% Triton X-100 when
required. DNA was stained with TO-PRO-3 (Molecular Probes). Cells
were mounted using Vectashield mounting medium (Vector Labora-
tories). Images were acquired using a LSM510 confocal laser coupled
to an Axiovert 100M inverted scanning microscope (Zeiss, Toronto,
CAN) and analyzed using LSM Image Browser version 3.2.0.70 (Zeiss,
Toronto, Canada).
Antibodies and Western blotting
Gal4 DNA-binding domain fusion proteins were detected in total
yeast extracts using a mouse monoclonal antibody against Gal4-DBD
from Santa Cruz Biotechnology (Cat: sc-510) and β-actinwas detected
using a mouse monoclonal antibody from Abcam (Cat: ab8224). GFP
fusion proteins were detected using a mixture of two mouse
monoclonal antibodies purchased from Roche (Cat: 11814460001)
and β-tubulin was detected using a mouse monoclonal antibody from
Sigma-Aldrich (Cat: T0426). Myc-Gam1 and endogenous Ubc9 were
detected using a c-Mycmousemonoclonal antibody (Cat: sc-40) and a
Ubc9 goat polyclonal antibody (Cat: sc-5231) from Santa Cruz
Biotechnology. For Western blot analysis, proteins were transferred
onto polyvinylidene diﬂuoride membranes and detected using
horseradish peroxidase-conjugated sheep anti-mouse secondary
antibody from GE healthcare (Cat: NA931) or a horseradish
peroxidase-conjugated rabbit anti-goat secondary antibody from
Santa Cruz Biotechnology (Cat: 2768) and an enhanced chemilumi-
nescence detection kit (GE Healthcare).
Transient HPV DNA replication assay
Transient HPV DNA replication was performed as described
previously (Titolo et al., 2003a). Brieﬂy, CHO-K1 cells were transfected
with three plasmids encoding HPV11 E1, E2, and theminimal origin of
DNA replication (pN9), respectively. Replication of the origin-
containing plasmid was quantiﬁed 48 h post-transfection by PCR
from Dpn1-digested genomic DNA. As a control, a fragment of the E1
expression plasmid devoid of Dpn1 restriction sites was ampliﬁed in
the same PCR reaction. A low number of PCR cycles were used toensure that ampliﬁcation reactions remain in the linear range (data
not shown). PCR products were separated on a 1% TBE agarose gel and
visualized by staining with the intercalating dye SYBRGreen I
(Molecular Probes). Amount of replicated ori-plasmid was quantiﬁed
by exposure on a STORM 860 Phosphorimager (Molecular Dynamics)
and normalized to the ampliﬁed E1 signal. Transfection and detection
of replicated ori plasmid were performed in quadruplicates.
Fluorescence anisotropy DNA-binding assay
The HPV11 and HPV16 E1 OBDs were expressed as fusions to GST
and puriﬁed from bacteria as described previously (Fradet-Turcotte et
al., 2007). The duplex DNA probe encoding two E1 binding sites was
described previously (Titolo et al., 2003a) and was prepared by
annealing a ﬂuorescein-labeled oligonucleotide to a complementary
oligonucleotide as described (Titolo et al., 2003a). Binding reactions
(150 μl) were assembled in 96-well HTRF plates (Packard) using
10 nM ﬂuorescein-labeled probe and the indicated concentrations of
protein in the following buffer: 20 mM Tris (pH 7.6), 50 mM NaCl,
0.01% NP-40, and 1 mM DTT. Fluorescence readings were recorded
and KD values calculated as previously described (Fradet-Turcotte et
al., 2007; Titolo et al., 2003a).Acknowledgments
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